Zobrazeno 1 - 10
of 52
pro vyhledávání: '"D. L. Wickerham"'
Autor:
SL Chia, D L Wickerham, Barry C. Lembersky, Mark L. Graham, James L. Wade, Sandra M. Swain, BT Hennessy, Soonmyung Paik, Charles E. Geyer, Adam Brufsky, Thomas E. Seay, Eleftherios P. Mamounas, SR Dakil, Louis Fehrenbacher, Hanna Bandos, Edward C. McCarron, Gamini S. Soori, Norman Wolmark
Publikováno v:
Cancer Research. 77:S1-05
Background: Extending adjuvant endocrine therapy (tx) after 5 yrs of tamoxifen (Tam) with either Tam or an AI improves disease-free survival (DFS) in early-stage breast cancer (BC). However, optimal duration of adjuvant AI tx beyond 5 yrs is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f154fb7eacf3c7e9e59b2fe70471b66
https://doi.org/10.1158/1538-7445.sabcs16-s1-05
https://doi.org/10.1158/1538-7445.sabcs16-s1-05
Autor:
Hanna Bandos, Worta McCaskill-Stevens, Angela Fagerlin, Therese B. Bevers, D L Wickerham, C. Holmberg, Tracy A. Battaglia
Publikováno v:
Cancer Research. 76:P6-10
Background: Tamoxifen and raloxifene are two selective receptor modulators (SERMs) that have been shown to reduce the risk of developing breast cancer in women at increased risk of the disease. Both drugs are infrequently used in the general U.S. pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bfbbb0f8ef9d35a25a0e69e390e9d60
https://doi.org/10.1158/1538-7445.sabcs15-p6-10-01
https://doi.org/10.1158/1538-7445.sabcs15-p6-10-01
Autor:
Daniel J. Schaid, James N. Ingle, Richard M. Weinshilboum, Celine M. Vachon, Norman Wolmark, Soonmyung Paik, Erin E. Carlson, Yusuke Nakamura, Matthew P. Goetz, D L Wickerham, Liewei Wang, Michiaki Kubo, Fergus J. Couch
Publikováno v:
Cancer Research. 75:P6-10
Purpose: Tamoxifen and raloxifene, are primary prevention strategies for women at high risk of breast cancer (Visvanathan, 2013). Recent advances in genetic studies of breast cancer risk have identified common susceptibility loci that explain 14% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::241a4c4fcb4cc3a92ce7ec548270a9d5
https://doi.org/10.1158/1538-7445.sabcs14-p6-10-03
https://doi.org/10.1158/1538-7445.sabcs14-p6-10-03
Autor:
Norman Wolmark, J-H Jeong, Soonmyung Paik, Diana B. Cherbavaz, S-R Kim, FL Baehner, Joseph P. Costantino, Steven M. Butler, S Shak, D L Wickerham, Gong Tang, Qing Liu, Barry C. Lembersky, Eleftherios P. Mamounas, Farid Jamshidian, Amy P. Sing, Thomas B. Julian
Publikováno v:
Cancer Research. 72:S1-10
Background: The RS result predicts outcome in N- and N+, ER+ pts treated with adjuvant endocrine therapy. RS also predicts benefit from adjuvant chemotherapy (CT) and pts with a high RS result receive most of the benefit. We evaluated the association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a87d8c9b2de5c49314cdd5082da59564
https://doi.org/10.1158/0008-5472.sabcs12-s1-10
https://doi.org/10.1158/0008-5472.sabcs12-s1-10
Autor:
Monika J. Thielen, Craig L. Slingluff, Robert Gray, Daniel J. Sargent, D L Wickerham, Hongkun Wang, Gina R. Petroni, Jacqueline Benedetti, Benjamin Djulbegovic, Anneke T. Schroen, Walter M. Cronin, Xiaofei Wang
Publikováno v:
Clinical Cancer Research. 18:256-262
Purpose: Assessing impact of poor accrual on premature trial closure requires a relevant metric. We propose defining accrual sufficiency on apparent ability to address primary endpoints (PE) rather than attaining accrual targets. Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cbdf4c31cda478fc2de060e1240f181
https://doi.org/10.1158/1078-0432.ccr-11-1633
https://doi.org/10.1158/1078-0432.ccr-11-1633
Autor:
Anneke T. Schroen, D L Wickerham, Benjamin Djulbegovic, Daniel J. Sargent, Xiaofei Wang, Robert Gray, Hongkun Wang, Gina R. Petroni, Jacqueline Benedetti, Monika J. Thielen, Craig L. Slingluff, Wendy F. Cohn, Walter M. Cronin
Publikováno v:
Clinical Trials. 8:591-600
Background Research on barriers to accrual has typically emphasized factors influencing participation after trial activation. Purpose We sought to identify factors influencing trial design and accrual predictions prior to trial activation associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef18d1ffdaf02173e6efd49c0e6cf5c1
https://doi.org/10.1177/1740774511419683
https://doi.org/10.1177/1740774511419683
Autor:
Peter C. Lucas, Zuzana Kos, Sunil Badve, Joseph P. Costantino, Priya Rastogi, Roberto Salgado, Hanna Bandos, Charles E. Geyer, Eleftherios P. Mamounas, Rim S. Kim, Norman Wolmark, Soonmyung Paik, Patrick G. Gavin, Louis Fehrenbacher, Sandra M. Swain, Nan Song, Gert Van den Eynden, Katherine L. Pogue-Geile, Giuseppe Floris, D L Wickerham
Publikováno v:
Journal of Clinical Oncology. 36:12010-12010
12010Background: Stromal tumor infiltrating lymphocytes (sTILs) in HER2-positive and triple-negative breast cancer (BC) are associated with prognosis and treatment response. NSABP B-31 evaluated ch...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bad7a87319c2f4aaf9cd2ff15350bef
https://doi.org/10.1200/jco.2018.36.15_suppl.12010
https://doi.org/10.1200/jco.2018.36.15_suppl.12010
Autor:
D L Wickerham, Jong-Hyeon Jeong, B Fisher, Norman Wolmark, Stewart J. Anderson, Eleftherios P. Mamounas, James J. Dignam
Publikováno v:
Scopus-Elsevier
Before 1989, credible information about the treatment of breast cancer was derived mainly from randomized clinical trials that enrolled women with either metastatic (stage IV); locally advanced (stage III); or primary, operable, axillary lymph node-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9483db3eb63a1e6fe51fa921b4191419
https://doi.org/10.1093/oxfordjournals.jncimonographs.a003463
https://doi.org/10.1093/oxfordjournals.jncimonographs.a003463
Autor:
Elizabeth Tan-Chiu, Maureen T. Kavanah, D L Wickerham, Steven E. Reis, Joseph P. Costantino, Jiping Wang
Publikováno v:
JNCI Journal of the National Cancer Institute. 93:16-21
Background The overall effect of prophylactic tamoxifen in women depends on the balance between the effects of the drug, which include preventing breast cancer and altering cardiovascular risk. In a recent clinical trial, postmenopausal estrogen-prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710fa7ccfba71be13b629efde807c350
https://doi.org/10.1093/jnci/93.1.16
https://doi.org/10.1093/jnci/93.1.16
Autor:
James J. Dignam, D L Wickerham, Linda H. Colangelo, Roy E. Smith, J Jones, Norman Wolmark, Wei Tian
Publikováno v:
JNCI Journal of the National Cancer Institute. 91:1933-1940
Background: African-Americans generally have lower survival rates from colon cancer than Caucasian Americans. This disparity has been attributed to many sources, including diagnosis at later disease stage and other unfavorable disease features, inade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e865afd2decafd35b727d4f9ff56c9
https://doi.org/10.1093/jnci/91.22.1933
https://doi.org/10.1093/jnci/91.22.1933